Evidence map›Paper›PMID 40038286›Full record

ArticleNature communications2025

Prospective cohort study of fatigue before and after SARS-CoV-2 infection in the Netherlands.

Anne J Huiberts, Siméon de Bruijn, Stijn P Andeweg, Christina E Hoeve, Maarten Schipper, Hester E de Melker, Janneke Hhm van de Wijgert, Susan van den Hof, Cees C van den Wijngaard, Mirjam J Knol

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anne J HuibertsCentre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.ORCID http://orcid.org/0000-0003-3206-9777
Siméon de BruijnCentre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
Stijn P AndewegCentre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.ORCID http://orcid.org/0000-0002-5488-5137
Christina E HoeveCentre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
Maarten SchipperDepartment of Statistics, Data Science and Modelling, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
Hester E de MelkerCentre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
Janneke Hhm van de WijgertJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands.ORCID http://orcid.org/0000-0003-2728-4560
Susan van den HofCentre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.ORCID http://orcid.org/0000-0002-2968-9652
Cees C van den WijngaardCentre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
Mirjam J KnolCentre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands. mirjam.knol@rivm.nl.ORCID http://orcid.org/0000-0003-0645-5754

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fatigue is one of the most common persistent symptoms of SARS-CoV-2 infection. We aimed to assess fatigue during and after a SARS-CoV-2 infection by age, sex, presence of a medical risk condition, SARS-CoV-2 variant and vaccination status, accounting for pre-infection fatigue and compared with uninfected individuals. We used data from an ongoing prospective cohort study in the Netherlands (VASCO). We included 22,705 first infections reported between 12 July 2021 and 9 March 2024. Mean fatigue scores increased during infection, declined rapidly in the first 90 days post-infection, but remained elevated until at least 270 days for Delta and 120 days for Omicron infections. Prevalence of severe fatigue was 18.5% before first infection. It increased to 24.4% and 22.5% during acute infection and decreased to 21.2% and 18.9% at 90 days after Delta and Omicron infection, respectively. The prevalence among uninfected participants was lower than among matched Delta-infected participants during the acute phase of the infection and 90 days post-infection. For matched Omicron-infected individuals this was only observed during the acute phase. We observed no differences in mean post- vs pre-infection fatigue scores at 90-270 days post-infection by vaccination status. The impact of SARS-CoV-2 infection on the prevalence of severe fatigue was modest at population level, especially for Omicron.

Indexed as

COVID-19FatigueSARS-CoV-2AdolescentAdultAgedFemaleHumansMaleMiddle AgedNetherlandsPrevalenceProspective StudiesRisk FactorsYoung Adult

Identifiers

PMID40038286
PMCPMC11880519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.